ROR2 and renal cell carcinoma: Phase I/II clinical trial is investigating the therapeutic effects of CAR-T CCT 301-38 or CCT 301-59 cells in stage IV metastatic patients at different molecular targets, that RCC patients with receptor orphan tyrosine kinase receptor 2 (ROR2) receive CCT31-59 while AXL-positive patients undergo CCT 301 − 38 (NCT03393936).